GlassScriptPhysician profile
Chelsea Thorn
NPI 1013451277
$2,625.01
in general payments reported to CMS, 2019-2025
25 companies · $705 in 2025
The $705 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.12 · 2022: $480 · 2023: $598 · 2024: $761 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519 · Travel and Lodging: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.22 |
| Travel and Lodging | $544.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $576.47 | 2024 | Intracept |
| Abbvie INC. | $505.45 | 2021-2025 | |
| Relievant Medsystems, INC. | $352.99 | 2023 | Intracept |
| Abbott Laboratories | $183.23 | 2022-2025 | Proclaim, Eterna, Octrode |
| Biotronik Nro, INC. | $160.54 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.01 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $141.46 | 2022-2025 | Ztlido |
| Protega Pharmaceutials INC | $126.17 | 2022 | |
| Averitas Pharma INC. | $77.09 | 2024-2025 | Qutenza |
| Amgen INC. | $40.86 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $35.10 | 2025 | Zilretta |
| Si-Bone, INC. | $34.12 | 2022-2025 | |
| Ucb, INC. | $27.50 | 2025 | Rystiggo |
| Allergan, INC. | $22.41 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.52 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $21.45 | 2022 | |
| Nevro Corp. | $18.28 | 2023 | Senza |
| Spr Therapeutics, INC | $18.22 | 2025 | Sprint Pns System |
| Lilly USA, LLC | $17.50 | 2022 | |
| Curonix LLC | $16.35 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Teva Pharmaceuticals USA, INC. | $15.69 | 2025 | Austedo Xr |
| Vertos Medical, INC. | $14.29 | 2022 | |
| Acacia Pharma INC | $14.20 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.31 | 2022 | |
| Biodelivery Sciences International, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Thorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.